Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells

BACKGROUND: Glioblastoma (GBM) is an aggressive brain tumor with universal recurrence and poor prognosis. The recurrence is largely driven by chemoradiation resistant cancer stem cells (CSCs). Epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are amplified in ~ 60% and ~ 30% of GBM pat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Exp Clin Cancer Res
Hlavní autoři: Vengoji, Raghupathy, Macha, Muzafar A., Nimmakayala, Rama Krishna, Rachagani, Satyanarayana, Siddiqui, Jawed A., Mallya, Kavita, Gorantla, Santhi, Jain, Maneesh, Ponnusamy, Moorthy P., Batra, Surinder K., Shonka, Nicole
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582495/
https://ncbi.nlm.nih.gov/pubmed/31215502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1264-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky